dart board miss failure
Biotech

Vertex drops asset in acute pain after phase 2 fail

All three dose levels of Nav1.8 inhibitor VX-993 failed to improve pain intensity over a 48-hour period compared to placebo.
Darren Incorvaia Aug 4, 2025 5:34pm
A ballpoint pen rests on top of a stack of documents ready for signing

Senate bill aims to keep NIH, CDC funds intact

Aug 4, 2025 11:30am
holiday Christmas presents shopping cart

Xoma shops for struggling biotechs, buying HilleVax and Lava

Aug 4, 2025 9:27am
red and purple piggy banks

OrbiMed gets $1.86B for latest fund despite ‘challenging’ market

Aug 4, 2025 10:25am
White arrow on a road pointing to the rising sun

Praxis' drug reduces seizures but sees 23% discontinuation rate

Aug 4, 2025 10:22am
closed close

Sirona closes R&D labs as Allergan deal, financing plans crumble

Aug 4, 2025 7:55am
More News

FDA formally kicks off medical device user fee negotiations

Aug 4, 2025 4:45pm

Synchron links BCI device to iPad through new Apple protocol

Aug 4, 2025 11:30am
Fierce Pharma

New Incyte CEO takes 'fresh look' at business, outlines BD plan

Aug 4, 2025 11:16am

Ultromics nets $55M for its AI cardiac ultrasound software

Aug 4, 2025 10:40am